Cover Image
市场调查报告书

速放性疼痛管理的预测

Immediate Release Pain Management to 2020

出版商 Greystone Research Associates 商品编码 302703
出版日期 内容信息 英文
商品交期: 最快1-2个工作天内
价格
Back to Top
速放性疼痛管理的预测 Immediate Release Pain Management to 2020
出版日期: 2014年05月21日 内容信息: 英文
简介

在先进地区的寿命延长,高龄化进行中,慢性疼痛及急性疼痛的罹患率、得病率也增加,从患者和家族生活品质的观点来看,对疼痛管理有高度关注。因应这个趋势,医药品开发经营者,以疼痛管理药品的新制剂化为焦点。经粘膜的疼痛管理,可能改善服药遵守,对应在高龄化和经济发展中特别成为问题的重要医疗课题。本市场,吸收性固体给药技术已应用于现有药物,在类似制剂成为新疼痛管理药重要给药途径之下,预测到2020年将达成强势成长。

本报告提供速放性疼痛管理药的市场相关调查、人口动态、得病率等市场环境与市场机会、速放性制剂的各种技术、主要产品的药物简介、市场上的地位、收益预测、新产品的开发情形、法律规章等的市场的各种影响因素分析等汇整。

摘要整理

疼痛管理市场

  • 进化的疼痛管理通信协议
  • 人口动态与疾病
  • 疼痛管理的地区性差异
  • 速放性疼痛管理
  • 癌症突发性疼痛
  • 目前环境
  • 未满足需求与市场机会

速放性制剂技术

  • 口颊片、口含锭
  • 口腔喷雾
  • 舌下含片
  • 鼻喷雾

癌症突发性疼痛市场

  • 支持市场
  • 人口动态和成长率
  • 竞争的药物类别
  • 市场预测

产品分析、市场上地位、收益的转变与预测

  • 粘膜速放性Fentanyl(TIRF:Transmucosal immediate-release fentanyl)
  • 口服药
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • 非专利速放性Fentanyl
  • 鼻腔药
  • Instanyl
  • Lazanda

开发阶段的IR疼痛管理药

  • Alfentanil
  • Sufentanil
  • 潜在性竞争药物治疗

市场系数

  • 法律规章
  • 独自制剂及技术
  • 联盟、联盟

企业简介

目录
Product Code: PMP492R

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to alternative formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, transmucosal pain management addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. We expect this market to experience healthy growth through 2020 as absorbable solid dosage technology is applied to existing drugs, and as similar formulations become an important route of administration for novel pain drugs

Highlights

  • Analyzes and evaluates the global market opportunity for immediate release pain management and assesses the probable impact of evolving regulatory, economic and demand factors
  • Assesses immediate release products approved or in development for the delivery of therapeutic pain management drugs
  • Provides detailed descriptions of pain management treatment segments, market factors, and business strategies
  • Forecasts immediate release pain management product demand to 2020
  • Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners

Table of Contents

  • Executive Summary
  • The Pain Management Market
  • Evolving Pain Management Protocols
  • Demographics and Disease
  • Regional Differences in Pain Management
  • Immediate Release Pain Management
  • Breakthrough Cancer Pain
  • The Current Landscape
  • The Unmet Need and Opportunity
  • Immediate Release Formulation Technologies
  • Buccal Films and Tablets
  • Oral Sprays
  • Sublingual Tablets
  • Nasal Sprays
  • The Market for Breakthrough Cancer Pain
  • The Addressable Market
  • Market Demographics and Growth
  • Competing Drug Classes
  • Market Projections
  • Product Analysis, Market Position Historical Revenue & Forecasts
  • Transmucosal Immediate-Release Fentanyl (TIRF)
  • Oral
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • Generic Immediate Release Fentanyl
  • Nasal
  • Instanyl
  • Lazanda
  • Development-Stage IR Pain Management Drugs
  • Alfentanil
  • Sufentanil
  • Potential Competing Drug Therapeutics
  • Market Factors
  • Regulatory Factors
  • Proprietary Formulations & Technology
  • Collaborations & Alliances
  • Company Profiles
Back to Top